Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes
| Autor: | Derosa G., D'Angelo A., Fogari E., Maffioli P., CICERO, ARRIGO FRANCESCO GIUSEPPE |
|---|---|
| Přispěvatelé: | Derosa G., Cicero A., D'Angelo A., Fogari E., Maffioli P. |
| Rok vydání: | 2011 |
| Předmět: |
Insulinresistance
Blood Glucose Inflammation Male Orlistat Body Weight nutritional and metabolic diseases Middle Aged Lipids Type 2 diabete Lactones Diabetes Mellitus Type 2 Double-Blind Method Humans Female Anti-Obesity Agents Obesity Insulin Resistance Nicotinamide Phosphoribosyltransferase Retinol-Binding Proteins Plasma Biomarkers Follow-Up Studies |
| Zdroj: | Journal of clinical pharmacy and therapeutics. 37(2) |
| ISSN: | 1365-2710 |
| Popis: | WHAT IS KNOWN AND OBJECTIVE: The behavioural approach is usually slow and not always sufficient to achieve optimal targets in weight and metabolic control in obese diabetic patients, and a pharmacological treatment is often necessary. The aim of this study was to compare the effects of orlistat and placebo on body weight, glycaemic and lipid profile and insulin resistance in patients with type 2 diabetes. METHODS: Two hundred and fifty-four obese, diabetic patients were enrolled in this study and randomized to take orlistat 360mg or placebo for 1year. We evaluated at baseline and after 3, 6, 9 and 12months body weight, waist circumference (WC), body mass index (BMI), glycated haemoglobin (HbA(1c) ), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), lipid profile, retinol-binding protein-4 (RBP-4), resistin, visfatin and high-sensitivity C-reactive protein (Hs-CRP). RESULTS AND DISCUSSION: We observed a significant reduction in body weight, WC, BMI, lipid profile, RBP-4 and visfatin in the orlistat group but not in control group. Faster improvements in HbA(1c) , PPG, FPI, HOMA-IR, resistin and Hs-CRP were recorded with orlistat than with placebo. A similar decrease in FPG was seen in the two groups. Significant predictors of change in insulin resistance (HOMA-IR) were RBP-4 and resistin concentration in the orlistat group (r=-0·53, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|